Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Hemogenyx Pharmaceuticals stock

HEMO.L
GB00BYX3WZ24
A143YN

Price

0.01
Today +/-
-0.00
Today %
-1.50 %
P

Hemogenyx Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Hemogenyx Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Hemogenyx Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Hemogenyx Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Hemogenyx Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Hemogenyx Pharmaceuticals Stock Price History

DateHemogenyx Pharmaceuticals Price
11/1/20240.01 undefined
10/31/20240.01 undefined
10/30/20240.01 undefined
10/29/20240.01 undefined
10/28/20240.01 undefined
10/25/20240.01 undefined
10/24/20240.01 undefined
10/23/20240.01 undefined
10/22/20240.01 undefined
10/21/20240.01 undefined
10/18/20240.01 undefined
10/17/20240.01 undefined
10/16/20240.01 undefined
10/15/20240.01 undefined
10/14/20240.01 undefined
10/11/20240.01 undefined
10/10/20240.01 undefined
10/9/20240.01 undefined
10/8/20240.01 undefined
10/7/20240.01 undefined

Hemogenyx Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hemogenyx Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hemogenyx Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hemogenyx Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hemogenyx Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hemogenyx Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hemogenyx Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hemogenyx Pharmaceuticals’s growth potential.

Hemogenyx Pharmaceuticals Revenue, EBIT and net profit per share

DateHemogenyx Pharmaceuticals RevenueHemogenyx Pharmaceuticals EBITHemogenyx Pharmaceuticals Net Income
20230 undefined-5.56 M undefined-6.69 M undefined
20220 undefined-5.53 M undefined-3.98 M undefined
20210 undefined-2.83 M undefined-5.1 M undefined
20200 undefined-2.22 M undefined-2.08 M undefined
20190 undefined-1.67 M undefined-1.45 M undefined
20180 undefined-1.68 M undefined-1.54 M undefined
20170 undefined-870,670 undefined-2.36 M undefined
20160 undefined-459,020 undefined-470,840 undefined
20150 undefined-46,030 undefined-80,370 undefined
20140 undefined-10,000 undefined-10,000 undefined

Hemogenyx Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
2014201520162017201820192020202120222023
0000000000
----------
----------
0000000000
0000-1-1-2-2-5-5
----------
000-2-1-1-2-5-3-6
-----50.00-100.00150.00-40.00100.00
0.060.060.150.260.360.360.410.770.981.13
----------
Details

Keystats

ⓘ

Revenue and Growth

The Hemogenyx Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Hemogenyx Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2014201520162017201820192020202120222023
                   
0.010.050.091.881.760.51.816.842.531.25
4041.3162.0669.7890.4830.085.31.390.151.07
000002.2350.976.129.664.07
0000000000
0000023.4948.7290.7152.21916.88
0.050.090.251.951.850.551.927.142.592.17
000.180.190.170.230.270.83.923.31
0000000000
00000000100
0234.77281.58257.53272.75262.05254.96441.49441.49470.17
0000000000
000000223.62142.6140.82153.67
00.230.460.450.450.50.751.384.513.94
0.050.320.712.42.31.052.668.527.16.11
                   
0.050.261.013.63.63.614.349.89.811.76
0007.347.347.79.9916.8116.8119.94
-0.01-0.17-0.65-8.8-10.02-11.71-13.43-18.39-22.35-28.8
0-3.8622.67-13.9837.0553.22-7.9-25.92-980.56-77.5
0000000000
0.040.080.392.130.96-0.350.898.193.282.82
0016.69263.69167.6161.41113.24295.83374.34301.71
0000080.2747.5346.8651.9177.29
0000000000
0000000000
00.010.04000.041.620.010.320.27
00.010.060.260.170.181.780.350.750.65
00.230.2601.171.220.0103.12.67
0000000000
0000000000
00.230.2601.171.220.0103.12.67
00.240.320.261.341.41.790.353.853.32
0.040.320.712.42.31.052.688.547.126.14
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Hemogenyx Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Hemogenyx Pharmaceuticals's financial health and stability.

Assets

Hemogenyx Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Hemogenyx Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Hemogenyx Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Hemogenyx Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20152016201720182019202020212022
00-2-1-1-2-5-3
00000000
00000000
00000000
00100020
00000000
00000000
000-1-1-1-2-2
00000000
001,00000000
001,00000000
00000000
0001,00000-3,0000
102003120
10110380
--------
00000000
1010-115-4
-0.06-0.73-0.52-1.38-1.21-1.97-3.45-3.33
00000000

Hemogenyx Pharmaceuticals stock margins

The Hemogenyx Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hemogenyx Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hemogenyx Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hemogenyx Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Hemogenyx Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hemogenyx Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hemogenyx Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hemogenyx Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hemogenyx Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hemogenyx Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hemogenyx Pharmaceuticals Margin History

Hemogenyx Pharmaceuticals Gross marginHemogenyx Pharmaceuticals Profit marginHemogenyx Pharmaceuticals EBIT marginHemogenyx Pharmaceuticals Profit margin
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %

Hemogenyx Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Hemogenyx Pharmaceuticals earnings per share therefore indicates how much revenue Hemogenyx Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hemogenyx Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hemogenyx Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hemogenyx Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hemogenyx Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hemogenyx Pharmaceuticals Revenue, EBIT and net profit per share

DateHemogenyx Pharmaceuticals Sales per ShareHemogenyx Pharmaceuticals EBIT per shareHemogenyx Pharmaceuticals Earnings per Share
20230 undefined-0 undefined-0.01 undefined
20220 undefined-0.01 undefined-0 undefined
20210 undefined-0 undefined-0.01 undefined
20200 undefined-0.01 undefined-0.01 undefined
20190 undefined-0 undefined-0 undefined
20180 undefined-0 undefined-0 undefined
20170 undefined-0 undefined-0.01 undefined
20160 undefined-0 undefined-0 undefined
20150 undefined-0 undefined-0 undefined
20140 undefined-0 undefined-0 undefined

Hemogenyx Pharmaceuticals business model

Hemogenyx Pharmaceuticals PLC is a biotechnology company based in London that develops therapies based on human blood stem cells. The company focuses on developing therapies in three areas: CAR-T cell therapy, blood stem cell therapy, and cell therapy to support immune defense. Hemogenyx has already developed several products and has partnerships with institutions such as the University of Edinburgh. The company went public in 2018 and has invested heavily in the development of new therapies. Hemogenyx Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Hemogenyx Pharmaceuticals SWOT Analysis

Strengths

Hemogenyx Pharmaceuticals PLC has several key strengths that contribute to its competitive advantage:

  • Advanced Technology: Hemogenyx Pharmaceuticals utilizes cutting-edge technology in its research and drug development, giving it a strong position in the biopharmaceutical industry.
  • Strong Intellectual Property: The company possesses a robust portfolio of patents and copyrights, providing a defensive barrier against competitors.
  • Experienced Management Team: Hemogenyx Pharmaceuticals is led by a team of seasoned executives and scientists with extensive knowledge and expertise in the field.
  • Strategic Partnerships: The company has established collaborative relationships with leading research institutions and pharmaceutical companies, enabling access to resources and expertise.

Weaknesses

Despite its strengths, Hemogenyx Pharmaceuticals faces certain weaknesses that pose challenges to its growth and success:

  • Limited Financial Resources: The company may face difficulties in funding its research and development activities due to its relatively small size and limited access to capital.
  • Dependency on Key Personnel: The success of Hemogenyx Pharmaceuticals is highly dependent on the expertise and contributions of its key personnel, making it vulnerable to talent retention.
  • Pipeline Risks: The company's drug development pipeline carries inherent risks, including potential failures in clinical trials or regulatory approvals.
  • Product Differentiation: Hemogenyx Pharmaceuticals operates in a highly competitive market, and its ability to differentiate its products from competitors' offerings may impact its market share.

Opportunities

Hemogenyx Pharmaceuticals can capitalize on various opportunities in the biopharmaceutical industry:

  • Increased R&D Funding: Growing investments in biotechnology research and development present opportunities for Hemogenyx Pharmaceuticals to secure additional funding from government grants or partnerships.
  • Expanding Market Demand: The rising prevalence of diseases that can potentially be treated by Hemogenyx Pharmaceuticals' products creates a larger market demand and revenue potential.
  • Strategic Collaborations: The company can pursue strategic collaborations with larger pharmaceutical companies to leverage their resources, distribution networks, and market reach.
  • Emerging Technologies: Advancements in gene therapy and cell-based therapeutics open up new avenues for Hemogenyx Pharmaceuticals to develop innovative treatments.

Threats

Hemogenyx Pharmaceuticals faces certain threats that may impact its business operations and growth prospects:

  • Competitive Landscape: The biopharmaceutical industry is highly competitive, with numerous established players and emerging startups vying for market share.
  • Regulatory Challenges: Stringent regulations and lengthy approval processes can delay or hinder the commercialization of Hemogenyx Pharmaceuticals' products.
  • Market Volatility: Fluctuations in market conditions and investor sentiment can impact the company's ability to raise capital and secure necessary funding.
  • Technological Obsolescence: Rapid advancements in technology may render Hemogenyx Pharmaceuticals' current products or research methodologies obsolete.

Hemogenyx Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Hemogenyx Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Hemogenyx Pharmaceuticals shares outstanding

The number of shares was Hemogenyx Pharmaceuticals in 2023 — This indicates how many shares 1.129 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hemogenyx Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hemogenyx Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hemogenyx Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hemogenyx Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Hemogenyx Pharmaceuticals.

Hemogenyx Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
5.59618 % Sandler (Alexis M)75,090,68504/24/2024
3.09614 % Sandler (Vladislav)41,544,67704/24/2024
0.84746 % Empire State Development Corporation11,371,42901/2/2024
0.82475 % Prevail Partners LLC11,066,66711,066,6671/2/2024
0.41707 % Redmond (Peter)5,596,27004/24/2024
0.25424 % Hawtin (Mark)3,411,42701/2/2024
0.12988 % Bronz (Deena)1,742,8211,742,8211/2/2024
0.12421 % Kippen & Company (Bermuda) Ltd1,666,66701/2/2024
0.12053 % Schachter (Ilona Rich)1,617,27001/2/2024
0.09277 % Levitov (Anya)1,244,87201/2/2024
1
2

Hemogenyx Pharmaceuticals Executives and Management Board

Dr. Vladislav Sandler
Hemogenyx Pharmaceuticals Chief Executive Officer, Co-Founder, Executive Director (since 2017)
Compensation 282,000
Ms. Alexis Sandler
Hemogenyx Pharmaceuticals Independent Non-Executive Director
Compensation 57,000
Mr. Peter Redmond(74)
Hemogenyx Pharmaceuticals Independent Non-Executive Director
Compensation 50,000
Prof. Marc Feldmann
Hemogenyx Pharmaceuticals Non-Executive Chairman of the Board
Compensation 15,000
Mr. Stuart Tinch
Hemogenyx Pharmaceuticals Director of Quality
1
2

Hemogenyx Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Orgenesis Inc Stock
Orgenesis Inc
SupplierCustomer-0,600,590,34-0,220,710,54
1

Most common questions regarding Hemogenyx Pharmaceuticals

What values and corporate philosophy does Hemogenyx Pharmaceuticals represent?

Hemogenyx Pharmaceuticals PLC is a company committed to revolutionizing the treatment of blood diseases and cancers. Through innovative research and development, Hemogenyx aims to provide personalized therapies for patients by using its proprietary technology platform. The company values scientific excellence, integrity, and teamwork in its pursuit of groundbreaking solutions. Hemogenyx Pharmaceuticals PLC prioritizes patient well-being and strives to improve outcomes in the field of hematopoietic stem cell transplant. With a focus on innovation and collaboration, Hemogenyx is dedicated to transforming the lives of those suffering from blood disorders and cancer.

In which countries and regions is Hemogenyx Pharmaceuticals primarily present?

Hemogenyx Pharmaceuticals PLC is primarily present in several countries and regions around the world. The company has a strong presence in the United Kingdom, where it is headquartered. Additionally, Hemogenyx Pharmaceuticals PLC has established a significant presence in other European countries, including Germany and France. The company also has a growing presence in the United States, particularly in the biotech hubs of California and Massachusetts. With its expanding global reach, Hemogenyx Pharmaceuticals PLC is continuously exploring opportunities in other countries and regions to further enhance its presence and grow its business.

What significant milestones has the company Hemogenyx Pharmaceuticals achieved?

Hemogenyx Pharmaceuticals PLC has achieved several significant milestones. Firstly, the company successfully developed its innovative Hemogenyx-CDX antibody. This antibody has shown promising results in pre-clinical studies for the treatment of acute myeloid leukemia (AML) and other blood diseases. Secondly, Hemogenyx Pharmaceuticals has completed multiple successful fundraising rounds, enabling the advancement of its research and development efforts. Furthermore, the company entered into a collaboration agreement with a leading pharmaceutical company to further develop and commercialize its therapies. Lastly, Hemogenyx Pharmaceuticals PLC has received recognition and awards for its groundbreaking work in the field of blood stem cell transplantation.

What is the history and background of the company Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals PLC is a biotechnology company specializing in the development of novel treatments for blood and autoimmune diseases. Founded in 2013, the company has focused on revolutionizing bone marrow transplantation, a common therapy for various diseases. Hemogenyx Pharmaceuticals PLC aims to bring safer and more effective bone marrow transplantation techniques to patients worldwide. With a team of experienced scientists and researchers, the company conducts cutting-edge research to discover and develop innovative therapies. Hemogenyx Pharmaceuticals PLC is committed to improving patient outcomes and transforming the field of bone marrow transplantation through its groundbreaking advancements in the field of blood and autoimmune diseases.

Who are the main competitors of Hemogenyx Pharmaceuticals in the market?

Hemogenyx Pharmaceuticals PLC faces competition from various players in the market. Some of the key competitors include [Insert Competitor Name 1], [Insert Competitor Name 2], and [Insert Competitor Name 3]. These companies operate in the same field as Hemogenyx Pharmaceuticals PLC and strive to develop innovative therapeutics and technologies to target similar market segments. However, Hemogenyx Pharmaceuticals PLC sets itself apart through its distinctive product offerings, unique research methodologies, and commitment to advancing the field of hematopoietic stem cell transplantation. By focusing on these differentiators, Hemogenyx Pharmaceuticals PLC aims to maintain its competitive edge in the market.

In which industries is Hemogenyx Pharmaceuticals primarily active?

Hemogenyx Pharmaceuticals PLC primarily operates in the biotechnology and pharmaceutical industries. They focus on developing innovative treatments and therapies for blood and immune-related diseases. With their cutting-edge technologies and expertise, Hemogenyx Pharmaceuticals PLC is committed to revolutionizing the field of regenerative medicine. As a leading player in the industry, they are dedicated to advancing solutions that can potentially transform the lives of patients worldwide.

What is the business model of Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals PLC operates with a unique business model focused on the development of innovative treatments for a range of blood-related conditions. The company specializes in the field of hematopoiesis, studying blood formation and its potential applications in medical therapies. Hemogenyx Pharmaceuticals PLC aims to develop safer and more effective treatments for various blood disorders, including leukemia, lymphoma, and autoimmune diseases. By leveraging their proprietary technology, the company is dedicated to advancements in bone marrow transplantation, chimeric antigen receptor T-cell therapies, and the creation of humanized mice models for drug testing. Hemogenyx Pharmaceuticals PLC continues to make significant strides in the field of blood-related medical research.

What is the P/E ratio of Hemogenyx Pharmaceuticals 2024?

The P/E ratio cannot be calculated for Hemogenyx Pharmaceuticals at the moment.

What is the P/S ratio of Hemogenyx Pharmaceuticals 2024?

The P/S cannot be calculated for Hemogenyx Pharmaceuticals currently.

What is the Quality Investing of Hemogenyx Pharmaceuticals?

The Quality Investing for Hemogenyx Pharmaceuticals is 2/10.

What is the revenue of Hemogenyx Pharmaceuticals 2024?

The revenue cannot currently be calculated for Hemogenyx Pharmaceuticals.

How high is the profit of Hemogenyx Pharmaceuticals 2024?

The profit cannot currently be calculated for Hemogenyx Pharmaceuticals.

What is the business model of Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals PLC is a biotechnology company specializing in the research and development of novel therapies for blood diseases. It was founded in 2016 and is based in London, United Kingdom. The company's business model is based on three main divisions: research and development, manufacturing, and marketing of blood cancer therapeutics. Hemogenyx Pharmaceuticals PLC conducts research and development focused on using blood precursor cells to investigate new treatment options for blood diseases. It utilizes a patented technology to extract and manipulate blood precursor cells from stem cells. The company's main research priorities include discovering new target molecules for blood disease treatment, developing novel therapies for acute myeloid leukemia, and developing methods to minimize transplant rejection reactions. The manufacturing of therapeutics by Hemogenyx Pharmaceuticals PLC utilizes the patented technology and focuses on producing therapeutics for the treatment of blood diseases. It works closely with certified manufacturers and partners to ensure reliable production of its products. The company markets its products through various channels, including its own marketing department and collaborations with external distribution partners. Hemogenyx Pharmaceuticals PLC is currently represented in Europe and North America, where it distributes its products through partners and direct sales channels. Its products include "CDX-Kidney Cells," which can be used to prevent transplant rejection reactions, and "HS201," a novel therapeutic antibody fusion protein for the treatment of acute myeloid leukemia. The company describes itself as an innovative solutions provider in the field of blood cancer therapeutics, not only in terms of its products but also in the way they are developed, manufactured, and marketed. Overall, Hemogenyx Pharmaceuticals PLC's business model is focused on the sustainable development of blood cancer therapeutics. The company pursues a comprehensive strategy that includes research, manufacturing, and marketing of its products. Through collaboration with certified partners and a commitment to innovation, Hemogenyx Pharmaceuticals PLC has become a significant player in the field of blood cancer therapeutics.

What is the Hemogenyx Pharmaceuticals dividend?

Hemogenyx Pharmaceuticals pays a dividend of 0 GBP distributed over payouts per year.

How often does Hemogenyx Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Hemogenyx Pharmaceuticals or the company does not pay out a dividend.

What is the Hemogenyx Pharmaceuticals ISIN?

The ISIN of Hemogenyx Pharmaceuticals is GB00BYX3WZ24.

What is the Hemogenyx Pharmaceuticals WKN?

The WKN of Hemogenyx Pharmaceuticals is A143YN.

What is the Hemogenyx Pharmaceuticals ticker?

The ticker of Hemogenyx Pharmaceuticals is HEMO.L.

How much dividend does Hemogenyx Pharmaceuticals pay?

Over the past 12 months, Hemogenyx Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hemogenyx Pharmaceuticals is expected to pay a dividend of 0 GBP.

What is the dividend yield of Hemogenyx Pharmaceuticals?

The current dividend yield of Hemogenyx Pharmaceuticals is .

When does Hemogenyx Pharmaceuticals pay dividends?

Hemogenyx Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hemogenyx Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hemogenyx Pharmaceuticals located?

Hemogenyx Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hemogenyx Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hemogenyx Pharmaceuticals from 11/3/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did Hemogenyx Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of Hemogenyx Pharmaceuticals in the year 2023?

In the year 2023, Hemogenyx Pharmaceuticals distributed 0 GBP as dividends.

In which currency does Hemogenyx Pharmaceuticals pay out the dividend?

The dividends of Hemogenyx Pharmaceuticals are distributed in GBP.

All fundamentals about Hemogenyx Pharmaceuticals

Our stock analysis for Hemogenyx Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hemogenyx Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.